Post-hoc analysis finds rivaroxaban can reduce adverse events in patients with ACS or chronic heart failure on DAPT
A post-hoc analysis of studies of post-acute coronary syndrome (ACS) or post-chronic heart failure (CHF) patients on dual antiplatelet therapy (DAPT) found that the addition of 2.5 mg of rivaroxaban twice daily led to a reduction in adverse events and all-cause mortality, according to late-breaking trial results presented Sunday at Cardiovascular Research Technologies (CRT) 2019.